Losec MUPS 20mg Gastro-resistant Tablets

  • Name:

    Losec MUPS 20mg Gastro-resistant Tablets

  • Company:
    info
  • Active Ingredients:

    omeprazole magnesium

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/01/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 14/1/2019

Click on this link to Download PDF directly

AstraZeneca Pharmaceuticals (Ireland) DAC

AstraZeneca Pharmaceuticals (Ireland) DAC

Company Products

Medicine NameActive Ingredients
Medicine Name Alvesco 160 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Alvesco 80 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Arimidex Active Ingredients Anastrozole
Medicine Name Atacand 8mg 16mg Tablets Active Ingredients Candesartan Cilexetil
Medicine Name Atacand Plus 16/12.5mg Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Medicine Name Bricanyl Turbohaler Active Ingredients Terbutaline sulfate
Medicine Name Brilique 60 mg film-coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg film coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg Orodispersible Tablets Active Ingredients Ticagrelor
Medicine Name Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen Active Ingredients Exenatide
Medicine Name Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen Active Ingredients Exenatide
Medicine Name Casodex 50mg Tablets Active Ingredients Bicalutamide
Medicine Name Crestor 5 mg, 10 mg, 20 mg and 40 mg Tablets Active Ingredients Rosuvastatin Calcium
Medicine Name Daxas 250 mcg Film-Coated Tablets Active Ingredients roflumilast
Medicine Name Daxas 500 mcg Film-coated Tablets Active Ingredients roflumilast
Medicine Name Fasenra 30 mg solution for injection in pre filled syringe Active Ingredients Benralizumab
Medicine Name Faslodex Active Ingredients Fulvestrant
Medicine Name Forxiga 10 mg Film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name Forxiga 5 mg film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name IMFINZI 50 mg/mL concentrate for solution for infusion Active Ingredients durvalumab
Medicine Name IRESSA 250 mg film-coated tablets Active Ingredients gefitinib
Medicine Name Komboglyze 2.5mg-1000mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Komboglyze 2.5mg-850mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Losec MUPS 10mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Losec MUPS 20mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
1 - 0 of 53 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 January 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 14 January 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 12 May 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 June 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 June 2017 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Improved presentation of SPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2-         Editorial changes

Section 4.8-         Addition of new side effect, ‘fundic gland polyps (benign)’

Section 10-         Revision date updated

Updated on 5 June 2017 PIL

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Improved presentation of SPC

Free text change information supplied by the pharmaceutical company

Section 4.2-         Editorial changes

Section 4.8-         Addition of new side effect, ‘fundic gland polyps (benign)’

Section 10-         Revision date updated

Updated on 31 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 February 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 –    Addition of information including CgA levels.

Section 5.1 –    Addition of information including CgA levels.

Section 10 –     Update to Date of Revision

Updated on 7 February 2017 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 4.4 –    Addition of information including CgA levels.

Section 5.1 –    Addition of information including CgA levels.

Section 10 –     Update to Date of Revision

Updated on 1 August 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2–        Changes relating to QRD update

Section 4.1 –    Changes relating to QRD update

Section 4.2 –    Changes relating to QRD update

Section 4.3 –    Changes relating to QRD update

Section 4.4 –    Addition of information to include Clostridium Difficile infections

Section 4.5 –    Changes relating to QRD update

Section 4.6 –    Changes relating to QRD update

Section 5.1 –    Changes relating to QRD update and addition of information to include Clostridium Difficile infections

Section 5.2 –    Changes relating to QRD update

Section 10 –     Update to Date of Revision

Updated on 1 August 2016 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 2–        Changes relating to QRD update

Section 4.1 –    Changes relating to QRD update

Section 4.2 –    Changes relating to QRD update

Section 4.3 –    Changes relating to QRD update

Section 4.4 –    Addition of information to include Clostridium Difficile infections

Section 4.5 –    Changes relating to QRD update

Section 4.6 –    Changes relating to QRD update

Section 5.1 –    Changes relating to QRD update and addition of information to include Clostridium Difficile infections

Section 5.2 –    Changes relating to QRD update

Section 10 –     Update to Date of Revision

Updated on 18 January 2016 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4 - Clinical particulars
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 2-        Editorial changes relating to latest QRD template

Section 4-        Editorial changes relating to latest QRD template

Section 4.2-     Editorial changes relating to latest QRD template

Section 4.4-     Addition of PRAC wording: ‘SCLE (subacute cutaneous lupus erythematosus)’

Section 4.6-     Editorial changes relating to latest QRD template

Section 4.8-     Addition of PRAC wording: ‘SCLE (subacute cutaneous lupus erythematosus)’and editorial changes relating to latest QRD template

Section 5.2-     Editorial changes relating to latest QRD template

Section 10 -     Update to Date of Revision

Updated on 18 January 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4 - Clinical particulars
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2-        Editorial changes relating to latest QRD template

Section 4-        Editorial changes relating to latest QRD template

Section 4.2-     Editorial changes relating to latest QRD template

Section 4.4-     Addition of PRAC wording: ‘SCLE (subacute cutaneous lupus erythematosus)’

Section 4.6-     Editorial changes relating to latest QRD template

Section 4.8-     Addition of PRAC wording: ‘SCLE (subacute cutaneous lupus erythematosus)’and editorial changes relating to latest QRD template

Section 5.2-     Editorial changes relating to latest QRD template

Section 10 -     Update to Date of Revision

Updated on 11 September 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

- Section 2      Reword the cross reference to section 6.1 in line with QRD template               
- Section 4.2   Reword of some subheadings in line with QRD template
- Section 4.3   Minor additions in line with QRD template
- Section 4.6   Reword the section heading in line with QRD. Fertility details added
- Section 4.8   Subheadings and reporting of suspected adverse reactions added in line with QRD template

- Section 5.1   Minor editorial changes in line with QRD template
- Section 5.2   Subheading changes in line with QRD

- Section 6.5   100 (2x50) added in packsize
- Section 10    Update date of this revision.

 

Updated on 11 September 2014 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Free text change information supplied by the pharmaceutical company

 

- Section 2      Reword the cross reference to section 6.1 in line with QRD template               
- Section 4.2   Reword of some subheadings in line with QRD template
- Section 4.3   Minor additions in line with QRD template
- Section 4.6   Reword the section heading in line with QRD. Fertility details added
- Section 4.8   Subheadings and reporting of suspected adverse reactions added in line with QRD template

- Section 5.1   Minor editorial changes in line with QRD template
- Section 5.2   Subheading changes in line with QRD

- Section 6.5   100 (2x50) added in packsize
- Section 10    Update date of this revision.

 

Updated on 3 March 2014 PIL

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

- Section 4.8 – Addition of side effect: hypomagnesaemia may also be associated with hypokalaemia.

- Section 10 – Date of revision

Updated on 3 March 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

- Section 4.8 – Addition of side effect: hypomagnesaemia may also be associated with hypokalaemia.

- Section 10 – Date of revision

Updated on 5 June 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

- Section 4.4 – editorial

- Section 4.5 – PK/PD info

- Section 4.8 – addition of severe hypomagnesaemia may result in hypocalcaemia

- Section 5.1 – Further info on CgA
- Section 10 - updated date of revision

Updated on 5 June 2013 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

- Section 4.4 – editorial

- Section 4.5 – PK/PD info

- Section 4.8 – addition of severe hypomagnesaemia may result in hypocalcaemia

- Section 5.1 – Further info on CgA
- Section 10 - updated date of revision

Updated on 2 November 2012 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.5


Addition of warning concerning co-administration with methotrexate.


Section 4.8

Addition of microscopic colitis as a side effect.


Section 10

Date of revision amended to 24th October 2012.

 

Updated on 2 November 2012 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 4.5


Addition of warning concerning co-administration with methotrexate.


Section 4.8

Addition of microscopic colitis as a side effect.


Section 10

Date of revision amended to 24th October 2012.

 

Updated on 23 August 2012 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 3

 

Removal of one tablet imprint design.

 

 

Section 4.4

 

Addition of information about severe hypomagnesaemia and increased risk of hip, wrist and spine fracture.

 

 

Section 4.8

 

Change of frequency descriptor for hypomagnesaemia and addition of Fracture of the hip, wrist or spine as an undesirable effect.

 

Section 6.1

 

Administrative updates to excipients.

 

 

Section 10

 

Update to "Date of Revision" to 15th August 2012.

Updated on 23 August 2012 PIL

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 3

 

Removal of one tablet imprint design.

 

 

Section 4.4

 

Addition of information about severe hypomagnesaemia and increased risk of hip, wrist and spine fracture.

 

 

Section 4.8

 

Change of frequency descriptor for hypomagnesaemia and addition of Fracture of the hip, wrist or spine as an undesirable effect.

 

Section 6.1

 

Administrative updates to excipients.

 

 

Section 10

 

Update to "Date of Revision" to 15th August 2012.

Updated on 2 February 2012 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4

 

New Paragraph inserted after Paragraph 4

 

Interference with laboratory tests

 

Increased CgA level may interfere with investigations for neuroendocrine tumours. To avoid this interference the omeprazole treatment should be temporarily stopped five days before CgA measurements.

 

Section 5.1

 

Other effects related to acid inhibition

 

Paragraph 3 amended to:

 

Chromogranin A (CgA) also increases due to decreased gastric acidity. This CgA modifying effect can not be demonstrated five days after stopping treatment with PPIs.

 

Section 10

 

Date of revision changed to 20th January 2012

 

Updated on 2 February 2012 PIL

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Free text change information supplied by the pharmaceutical company

Section 4.4

 

New Paragraph inserted after Paragraph 4

 

Interference with laboratory tests

 

Increased CgA level may interfere with investigations for neuroendocrine tumours. To avoid this interference the omeprazole treatment should be temporarily stopped five days before CgA measurements.

 

Section 5.1

 

Other effects related to acid inhibition

 

Paragraph 3 amended to:

 

Chromogranin A (CgA) also increases due to decreased gastric acidity. This CgA modifying effect can not be demonstrated five days after stopping treatment with PPIs.

 

Section 10

 

Date of revision changed to 20th January 2012